List of Excipients in Branded Drug ZOLPIDEM TARTRATE SUBLINGUAL

Generic Drugs Containing ZOLPIDEM TARTRATE SUBLINGUAL

Company	Ingredient	NDC	Excipient
ENDO USA Inc	zolpidem tartrate sublingual	49884-898	CROSPOVIDONE
ENDO USA Inc	zolpidem tartrate sublingual	49884-898	MAGNESIUM STEARATE
ENDO USA Inc	zolpidem tartrate sublingual	49884-898	MANNITOL
ENDO USA Inc	zolpidem tartrate sublingual	49884-898	PEPPERMINT

What are the Most Frequently-Used Excipients in ZOLPIDEM TARTRATE SUBLINGUAL?

# Of NDCs	Excipient
1	CROSPOVIDONE
1	MAGNESIUM STEARATE
1	MANNITOL
1	PEPPERMINT

Zolpidem Tartrate Sublingual Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Zolpidem tartrate sublingual products have a differentiated commercial position because they deliver a low dose of zolpidem through the oral mucosa for patients who wake during the night and have at least four hours remaining before planned awakening. The principal opportunity is not a new active ingredient. It is a fast-disintegrating, taste-controlled dosage form with reliable low-dose content uniformity, acceptable mucosal exposure, and a clear regulatory pathway.

Intermezzo, the reference product, contains 1.75 mg or 3.5 mg of zolpidem tartrate equivalent to zolpidem. The FDA approved the product in 2011 under NDA 022739 for middle-of-the-night insomnia.[1] Its commercial prospects are strongest in generic substitution, lifecycle reformulation, contract manufacturing, and differentiated low-dose sleep products.

What excipients are used in zolpidem tartrate sublingual tablets?

The reference product uses a conventional direct-compression excipient platform centered on a rapidly soluble filler, superdisintegrant, glidant, lubricant, and sweetener. The FDA prescribing information identifies mannitol, microcrystalline cellulose, sodium starch glycolate, silicon dioxide, magnesium stearate, and sucralose among the inactive ingredients.[1]

Excipient function	Likely reference-product role	Commercial purpose
Mannitol	Soluble diluent and mouthfeel modifier	Promotes rapid dissolution and cooling sensation
Microcrystalline cellulose	Compacting filler and structural carrier	Supports tablet strength at low drug load
Sodium starch glycolate	Superdisintegrant	Accelerates tablet breakup in saliva
Colloidal silicon dioxide	Glidant and flow aid	Improves blend flow and content uniformity
Magnesium stearate	Lubricant	Supports ejection from the tablet press
Sucralose	High-intensity sweetener	Masks zolpidem bitterness

The low dose creates a major formulation constraint. In the 1.75 mg strength, zolpidem tartrate is a small fraction of total tablet mass. Blend uniformity, segregation control, particle-size matching, and validated sampling plans are therefore more important than simply increasing disintegrant concentration.

Which excipients are most important for sublingual performance?

Mannitol and sodium starch glycolate are central to the performance profile. Mannitol provides a rapidly dissolving matrix and favorable mouthfeel. Sodium starch glycolate promotes rapid liquid uptake and tablet rupture. Microcrystalline cellulose contributes mechanical strength but can slow dissolution if used at excessive levels.

A commercial formulation should balance four variables:

1. Tablet tensile strength.
2. Disintegration time in a small saliva volume.
3. Drug dissolution and dose uniformity.
4. Taste and residual mouthfeel.

The lubricant level requires tight control. Excess magnesium stearate can reduce wetting and slow dissolution, particularly in a low-dose tablet where the drug must rapidly leave the compact.

What excipient strategy is optimal for zolpidem sublingual tablets?

The most defensible strategy is a simple, low-excipient direct-compression system with a soluble filler, a high-efficiency disintegrant, taste masking, and limited hydrophobic lubricant.

Direct-compression platform

Direct compression minimizes manufacturing steps and reduces exposure to heat and water. That is useful for a product intended to disintegrate rapidly and for a low-dose active that requires tight blend-control procedures.

A development formulation would typically screen:

• Mannitol grades with different particle sizes and compressibility.
• Microcrystalline cellulose grades with different compactibility profiles.
• Sodium starch glycolate at low and moderate concentrations.
• Crospovidone as an alternative or co-disintegrant.
• Sucralose, acesulfame potassium, or taste-masking polymers.
• Magnesium stearate versus sodium stearyl fumarate.

Sodium stearyl fumarate may provide a lower-hydrophobicity lubrication option, but it can change tablet ejection, hardness, and dissolution behavior. The choice should be driven by dissolution and sensory data, not by excipient novelty.

Taste-masking strategy

Zolpidem has a bitter taste. Sublingual delivery increases the importance of taste because the dosage form contacts the tongue before swallowing. Sucralose alone may be adequate for some formulations, but stronger commercial differentiation could come from:

• Drug-layer coating or microencapsulation.
• Ion-exchange resin complexes.
• Polymer barriers that dissolve rapidly after placement.
• Flavored mannitol-based matrices.
• Multiparticulate compression with coated zolpidem particles.

Taste masking must not materially delay sublingual drug release. A coating designed for conventional oral tablets may produce an unacceptable lag in a sublingual product.

Low-dose content uniformity

The 1.75 mg strength presents greater manufacturing risk than the 3.5 mg strength. A robust process should use geometric dilution, controlled addition of the active, matched particle-size distributions, low-shear blending where appropriate, and in-process blend uniformity testing.

The product should be evaluated for:

• Blend uniformity.
• Dosage-unit uniformity.
• Tablet friability.
• Breaking force.
• In-vitro disintegration.
• Dissolution in low-volume aqueous media.
• Residual drug after simulated sublingual residence.
• Stability under humidity stress.

The active-to-excipient ratio also affects the regulatory burden. A formulation that uses a highly concentrated premix can improve manufacturing control but may introduce an additional premixing operation and segregation risk.

What formulations are protected by zolpidem sublingual patents?

The principal historical patent platform covered sublingual zolpidem compositions and their use for treating insomnia. U.S. Patent No. 6,514,531 was assigned to Transcept Pharmaceuticals and was associated with the sublingual zolpidem product platform.[2]

Patent issue	Commercial relevance
Sublingual dosage form	Protects delivery route and dosage-form architecture
Rapid disintegration	May distinguish the product from conventional oral zolpidem
Low-dose administration	Supports middle-of-the-night dosing
Taste acceptability	Can support product differentiation if claimed
Method of treating insomnia	May create method-of-use exposure depending on claim scope
Manufacturing process	Can create a separate barrier if process claims remain enforceable

The core historical patent term has expired. Commercial analysis must separate expired platform claims from later-issued formulation, manufacturing, or method-of-use claims. A generic applicant also must review FDA Orange Book listings, Paragraph IV certifications, pediatric extensions, and any applicable patent-term adjustments.

Are there formulation patents for zolpidem sublingual products?

Formulation patents can target particle engineering, taste masking, disintegration performance, tablet composition, or specific excipient ranges. Their value depends on claim breadth. A patent limited to a narrow ratio of mannitol, microcrystalline cellulose, and superdisintegrant may be easier to design around than a patent covering a functional performance threshold.

For a new entrant, freedom-to-operate analysis should focus on:

• Sublingual zolpidem composition claims.
• Rapid-release tablet claims.
• Taste-masked zolpidem particles.
• Low-dose content-uniformity manufacturing methods.
• Specific-use claims for middle-of-the-night awakening.
• Patent families owned by the reference-product sponsor or licensed technology providers.

What is the FDA regulatory status of zolpidem tartrate sublingual?

Intermezzo was approved through the 505(b)(2) pathway as a new dosage form of an already approved active ingredient.[1] A follow-on sponsor has two principal routes.

ANDA strategy

An ANDA is appropriate where the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug. The applicant must match the reference product’s dosage form, strengths, route, and key quality attributes.

The principal ANDA risks are:

• Difficulty demonstrating bioequivalence for a sublingual product.
• Differences in excipients that change local or systemic exposure.
• Failure to match disintegration or dissolution behavior.
• Patent certification exposure.
• Reference-product availability and product discontinuation issues.

505(b)(2) strategy

A 505(b)(2) application may support a product with a new excipient system, improved taste, different strength, altered dosing instructions, or a modified sublingual delivery mechanism. This route is more suitable where the product seeks a clinical or usability distinction rather than a direct generic substitution.

Potential 505(b)(2) positioning includes:

• Improved taste masking.
• Smaller tablet size.
• Lower residual mouthfeel.
• Faster disintegration.
• A new strength for selected patient populations.
• Packaging that reduces medication errors.
• A formulation designed for patients with difficulty swallowing.

The 505(b)(2) route can generate three-year marketing exclusivity for certain new clinical investigations, but it does not create five-year new chemical entity exclusivity because zolpidem is an established active ingredient.[3]

When does zolpidem sublingual lose exclusivity?

The main historical composition patent associated with Intermezzo expired around 2020, subject to patent-term calculations and any applicable extensions.[2] FDA regulatory exclusivity and patent exclusivity must be analyzed separately.

Exclusivity category	Relevance to zolpidem sublingual
New chemical entity exclusivity	Not available for zolpidem
Five-year new-drug exclusivity	Not applicable to this reformulation
Three-year clinical-investigation exclusivity	Possible for a qualifying 505(b)(2) application
Pediatric exclusivity	Available only if FDA grants it for qualifying studies
Patent exclusivity	Depends on issued claims and term adjustments
Orphan exclusivity	Not applicable to ordinary insomnia treatment

The commercial entry date depends on more than the earliest patent expiration. It also depends on ANDA approval timing, Paragraph IV litigation, settlement terms, regulatory exclusivity, manufacturing readiness, and the sponsor’s decision to launch at risk.

How do Paragraph IV challenges affect zolpidem sublingual?

A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If the patent holder files an infringement action within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments.[4]

For zolpidem sublingual, a Paragraph IV strategy would likely focus on:

• Non-infringement based on excipient selection.
• Absence of claimed particle-size or coating characteristics.
• Invalidity based on prior art involving sublingual hypnotics.
• Lack of written description for broad functional claims.
• Obviousness of combining mannitol, a superdisintegrant, and a sweetener.
• Expired patent claims.

The strongest design-around opportunity is a formulation that changes the claimed composition while preserving the product’s critical performance attributes. A sponsor should avoid copying a patented excipient ratio where a functional alternative can achieve comparable disintegration and taste.

What generic launch risks exist for zolpidem sublingual?

A generic launch faces a smaller patent barrier than a conventional new molecular entity but a higher technical risk than a standard immediate-release tablet.

Technical risks

The largest technical risks are dose uniformity, saliva-volume sensitivity, taste, and performance at the lower strength. A product may pass conventional dissolution testing yet fail to provide convincing sublingual performance if the method does not represent actual oral conditions.

Regulatory risks

FDA labeling includes important safety restrictions related to next-day impairment, dosing frequency, sex-specific dosing considerations, and the requirement that patients have sufficient time remaining for sleep.[1] A generic or 505(b)(2) product must preserve the relevant safety information unless FDA approves a justified labeling difference.

Commercial risks

The market is narrower than the market for conventional zolpidem tablets. The product addresses a specific use case: patients who awaken during the night and have sufficient remaining sleep time. Commercial uptake depends on physician recognition, payer coverage, patient preference, and the availability of lower-cost generic alternatives.

What commercial opportunities exist for zolpidem sublingual excipients?

The strongest opportunities are formulation-enabling rather than excipient-licensing opportunities.

Generic and authorized-generic supply

A manufacturer with established direct-compression capacity can compete through:

• Low-cost mannitol-based tablets.
• Reliable 1.75 mg and 3.5 mg production.
• Small-batch flexibility.
• Regional or private-label supply.
• Packaging and serialization services.

505(b)(2) reformulation

A differentiated product could target patient experience rather than pharmacology. Candidate attributes include improved taste, lower tablet mass, faster perceived onset, and packaging that separates the 1.75 mg and 3.5 mg strengths.

Excipient supplier partnerships

Excipient suppliers can create value through:

• Co-processed mannitol-cellulose systems.
• Direct-compression grades optimized for low-dose drugs.
• Rapidly dispersing excipient blends.
• Taste-masking platforms.
• Low-hydrophobicity lubricants.
• Regulatory support packages for global submissions.

The strongest supplier proposition is a reproducible platform that improves content uniformity and compression without slowing dissolution.

How does zolpidem sublingual compare with competing sleep products?

Product category	Main advantage	Main limitation	Excipient opportunity
Conventional zolpidem tablet	Low cost and broad familiarity	Swallowing and delayed use after awakening	Limited
Zolpidem extended release	Sleep-maintenance positioning	Greater next-day impairment concerns	Modified-release polymers
Zolpidem sublingual	Convenient middle-of-night administration	Narrow use case and taste burden	Rapid disintegration and taste masking
Melatonin products	Consumer accessibility	Variable efficacy and product quality	Flavor, chewable, and fast-dissolve formats
Orexin antagonists	Different pharmacology and sleep profile	Higher branded cost	Tablet swallowability and coating
Zaleplon and other short-acting hypnotics	Shorter duration in some use cases	Separate safety and efficacy profile	Conventional immediate-release systems

Zolpidem sublingual has a distinct administration benefit, but the product must preserve rapid availability without increasing residual impairment. That balance limits the value of aggressive absorption-enhancement technologies.

What is the revenue exposure and competitive landscape?

The commercial opportunity is a specialty generic or niche reformulation market rather than a broad blockbuster opportunity. Revenue depends on whether the sponsor captures the reference-product market, secures preferred payer placement, or differentiates through a 505(b)(2) label.

Key competitive groups include:

• Generic manufacturers with low-dose direct-compression capability.
• Contract development and manufacturing organizations.
• Specialty pharmaceutical companies pursuing 505(b)(2) products.
• Excipient suppliers with taste-masking and orally disintegrating tablet platforms.
• Branded insomnia companies competing for the same nighttime-use population.

No biosimilar risk applies. Zolpidem tartrate is a small-molecule active ingredient, and the relevant competition is generic, reformulated, or therapeutically substitutive rather than biosimilar.

Key Takeaways

• Mannitol, microcrystalline cellulose, sodium starch glycolate, silicon dioxide, magnesium stearate, and sucralose form the core excipient logic for a reference-like product.
• The 1.75 mg strength creates the greatest content-uniformity and blend-segregation risk.
• Taste masking must improve acceptability without delaying sublingual release.
• The historic core patent platform is associated with U.S. Patent No. 6,514,531 and has reached the end of its ordinary commercial life.[2]
• ANDA development offers the lowest-cost route when pharmaceutical equivalence and bioequivalence are achievable.
• A 505(b)(2) product has greater flexibility to claim taste, usability, strength, or delivery improvements.
• Excipient suppliers have the clearest opportunity in co-processed direct-compression systems, taste masking, and low-dose manufacturing support.
• The market is commercially viable as a targeted generic or specialty reformulation opportunity, not as a new chemical entity market.
• No biosimilar pathway applies.

FAQs

Can crospovidone replace sodium starch glycolate in zolpidem sublingual tablets?

Yes. Crospovidone can provide rapid liquid uptake and tablet breakup, but the replacement changes compaction, dissolution, friability, and mouthfeel. The formulation must be reoptimized rather than substituted on a one-for-one basis.

Is a co-processed mannitol excipient commercially attractive for zolpidem sublingual?

Yes. A co-processed mannitol system may improve flow, compressibility, and low-dose blend uniformity. Its value is highest where it reduces manufacturing variability without increasing tablet size or slowing disintegration.

Can a zolpidem sublingual product use a novel sweetener and obtain 505(b)(2) approval?

A novel sweetener alone is unlikely to justify a meaningful regulatory distinction. A 505(b)(2) case is stronger when the excipient change produces documented improvements in taste, tolerability, dose administration, or product performance supported by appropriate studies.

Are orally disintegrating zolpidem tablets equivalent to sublingual zolpidem tablets?

No. An orally disintegrating tablet is generally designed to disintegrate in the mouth and be swallowed, while a sublingual tablet is intended for administration under the tongue and may rely on different release and exposure characteristics. The regulatory pathway depends on the proposed labeling and performance claims.

What packaging is best for zolpidem tartrate sublingual tablets?

Unit-dose blister packaging is generally preferable because it protects low-dose tablets from humidity, supports dose identification, and reduces handling errors. Packaging should clearly distinguish the 1.75 mg and 3.5 mg strengths and reinforce the product’s middle-of-the-night dosing instructions.

References

1. U.S. Food and Drug Administration. (2011). Intermezzo (zolpidem tartrate) sublingual tablets prescribing information. NDA 022739.

2. U.S. Patent No. 6,514,531. (2003). Sublingual pharmaceutical compositions comprising zolpidem. U.S. Patent and Trademark Office.

3. U.S. Food and Drug Administration. (2019). Small business assistance: Frequently asked questions on the New Drug Product Exclusivity. FDA.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.